Selected first-line series of blastoid MCL
| References . | Blastoid MCL, n (% of total) . | Regimen . | OR (%)/CR (%) . | EFS/PFS . | Median OS . |
|---|---|---|---|---|---|
| Conventional regimens (retrospective) | |||||
| Bernard et al32 | 33 (100) | Mostly CHOP, CVP | n.a./36 | 13 mo (median) | 14.5 mo |
| Bhatt et al31 | 32 (19) | CHOP (62%), hyper-CVAD (32%) | 68/58 | 16% (5 y) | 24% (5 y) |
| Robak et al64 | 34 (7; Ki-67 > 30%) | R-CHOP VR-CAP | n.a. | 8.6 mo 15.0 mo | n.a. |
| Dose-intensified regimens | |||||
| Chihara et al49 | 14 (14) | R–hyper-CVAD, R-MTX, and Ara-C | n.a./87 | 6.8 y | 43% (8 y) |
| Geisler and colleagues41,42 | 31 (19) | R–maxi-CHOP, alternating Ara-C, autologous SCT | n.a./54 | 44% (10 y) | 51% (10 y) |
| Damon et al45 | 12 (15) | R-maxi-CHOP, etoposide/Ara-C, autologous SCT | n.a./69 | 56% (5 y) | 64% (5 y) |
| Hermine and colleagues6,46 | 28 (9) | R-CHOP with or without alternating R-DHAP, autologous SCT | 81/23 | 18 mo (median) | 32 mo (median) |
| Kluin-Nelemans6,36 | 62 (10) | R-CHOP vs R-FC → IFN vs rituximab maintenance | 81/23 | 19 mo (median) | 29 mo (median) |
| References . | Blastoid MCL, n (% of total) . | Regimen . | OR (%)/CR (%) . | EFS/PFS . | Median OS . |
|---|---|---|---|---|---|
| Conventional regimens (retrospective) | |||||
| Bernard et al32 | 33 (100) | Mostly CHOP, CVP | n.a./36 | 13 mo (median) | 14.5 mo |
| Bhatt et al31 | 32 (19) | CHOP (62%), hyper-CVAD (32%) | 68/58 | 16% (5 y) | 24% (5 y) |
| Robak et al64 | 34 (7; Ki-67 > 30%) | R-CHOP VR-CAP | n.a. | 8.6 mo 15.0 mo | n.a. |
| Dose-intensified regimens | |||||
| Chihara et al49 | 14 (14) | R–hyper-CVAD, R-MTX, and Ara-C | n.a./87 | 6.8 y | 43% (8 y) |
| Geisler and colleagues41,42 | 31 (19) | R–maxi-CHOP, alternating Ara-C, autologous SCT | n.a./54 | 44% (10 y) | 51% (10 y) |
| Damon et al45 | 12 (15) | R-maxi-CHOP, etoposide/Ara-C, autologous SCT | n.a./69 | 56% (5 y) | 64% (5 y) |
| Hermine and colleagues6,46 | 28 (9) | R-CHOP with or without alternating R-DHAP, autologous SCT | 81/23 | 18 mo (median) | 32 mo (median) |
| Kluin-Nelemans6,36 | 62 (10) | R-CHOP vs R-FC → IFN vs rituximab maintenance | 81/23 | 19 mo (median) | 29 mo (median) |
Ara-C, cytarabine; CVP, cyclophosphamide, vincristine, prednisone; EFS, event-free survival; Hyper-CVAD, cyclophosphamide, doxorubicine, dexamethasone; IFN, interferon; n.a., not available; OR, overall response; R-DHAP, dexamethasone, high dose cytarabine, cisplatinum; R-FC, rituximab, fludarabine, cyclophosphamide; R-maxi-CHOP, rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone; R-Mtx, rituximab-methotrexate; SCT, stem cell transplantation.